GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Total Equity

Acasti Pharma (Acasti Pharma) Total Equity : $64.68 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma Total Equity?

Acasti Pharma's total equity for the quarter that ended in Dec. 2023 was $64.68 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Acasti Pharma Total Equity Historical Data

The historical data trend for Acasti Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Total Equity Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.05 12.99 55.66 108.27 67.96

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.72 67.96 64.01 66.75 64.68

Acasti Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Acasti Pharma's Total Equity for the fiscal year that ended in Mar. 2023 is calculated as

Total Equity=Total Assets(Q: Mar. 2023 )-Total Liabilities(Q: Mar. 2023 )
=79.123-11.168
=67.96

Acasti Pharma's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=76.185-11.505
=64.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acasti Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (Acasti Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Total Equity
Comparable Companies
NTBL BIXT AIM PIRS NBIO AURX CLCS MRKR NLSP AGE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
A1P0:Germany
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Website
https://www.acastipharma.com
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202